Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Cai, Zhen  [Clear All Filters]
2024
Guan F, Yang L, Chen Y, Shi J, Song X, Lai X, Lu Y, Liu L, Ouyang G, Zhao Y, et al. Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study. Cancer. 2024.
Jin D, Chen H, He J, Li Y, Zheng G, Yang Y, Zhao Y, Le J, Shu W, He D, et al. Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia. Target Oncol. 2024.
Jiang B, Zhao Y, Luo Y, Yu J, Chen Y, Ye B, Fu H, Lai X, Liu L, Ye Y, et al. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring Rearrangement and Its Prognostic Factors. Cell Transplant. 2024;33:9636897231225821.
2023
Zhao Y, Huang X, Zhang YJ, He D, He J, Zhang E, Chen M, Liu Q, Chen J, Cai Z. Assessing cell chimerism in an acute graft-versus-host disease model established in TLR4 knockout mice. Cir Cir. 2023;91(5):601-614.
Yang T, Jiang B, Luo Y, Zhao Y, Ouyang G, Yu J, Lan J, Lu Y, Lai X, Ye B, et al. Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms. Am J Hematol. 2023.
Guan F-S, He D-H, Li Y, Zhang Y, Zheng G-F, Zhu Y-Y, He J-S, Zhang E-F, Cai Z, Zhao Y. [Efficacy and Safety of Plerixafor Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Lymphoma Patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023;31(4):1056-1060.
An Z-Y, Wu Y-J, Hou Y, Mei H, Nong W-X, Li W-Q, Zhou H, Feng R, Shen J-P, Peng J, et al. A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study. Sci Bull (Beijing). 2023.
Yuan X-L, Lai X-Y, Wu Y-B, Yang L-X, Shi J-M, Liu L-Z, Yu J, Zhao Y-M, Zheng W-Y, He J-S, et al. A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation. Bone Marrow Transplant. 2023.
Sun H, Liu A, Liu L, Wang W, Cai Z, Yan H, Chen L, Gao G, Wang F, Liao A, et al. Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China. BMC Cancer. 2023;23(1):930.
Jin D, He J, Wu W, Han X, Le J, Shu W, Fu J, Kong H, Wang G, Zhou X, et al. Outcomes of COVID-19 in multiple myeloma patients treated with daratumumab. Cancer Sci. 2023.
Wu L, Wu Y, Shi J, Lai X, Zhao Y, Liu L, Yu J, Yang L, Zhu P, Zheng W, et al. Survival and late mortality among patients who survived disease-free for 2 years after stem cell transplantation. Br J Haematol. 2023.
2022
He D, Zhu C, Guo X, Huang X, Han X, Zheng G, Zhao Y, Yang Y, Wu W, Ge J, et al. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients. Transfus Apher Sci. 2022:103618.
2014
Zi F-M, He J-S, Li Y, Wu C, Wu W-J, Yang Y, Wang L-J, He D-H, Yang L, Zhao Y, et al. Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway. Cancer Biol Ther. 2014;15(10).